Targeting lupus nephritis could be a more straightforward path to market for new lupus drugs – or at least that is what some drug makers are hoping. Lupus nephritis effects a smaller subset of patients than the more common systemic lupus erythematosus (SLE) and it could have some advantages when it comes to drug development: diagnosis is done by a test, the clinical endpoints are well defined, the condition can be life-threatening, and there are no approved treatments.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?